Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours.

van Essen M, Krenning EP, Kam BL, de Herder WW, van Aken MO, Kwekkeboom DJ.

Eur J Nucl Med Mol Imaging. 2008 Apr;35(4):743-8. doi: 10.1007/s00259-007-0688-7. Epub 2008 Jan 11.

2.

177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide.

Hubble D, Kong G, Michael M, Johnson V, Ramdave S, Hicks RJ.

Eur J Nucl Med Mol Imaging. 2010 Oct;37(10):1869-75. doi: 10.1007/s00259-010-1483-4. Epub 2010 May 6.

PMID:
20445977
3.

Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours.

Claringbold PG, Brayshaw PA, Price RA, Turner JH.

Eur J Nucl Med Mol Imaging. 2011 Feb;38(2):302-11. doi: 10.1007/s00259-010-1631-x. Epub 2010 Oct 30.

PMID:
21052661
4.

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate.

Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, de Jong M, Srinivasan A, Erion JL, Krenning EP.

Eur J Nucl Med Mol Imaging. 2003 Mar;30(3):417-22. Epub 2003 Jan 9.

5.

Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.

Kesavan M, Claringbold PG, Turner JH.

Neuroendocrinology. 2014;99(2):108-17. doi: 10.1159/000362558. Epub 2014 Apr 4.

PMID:
24714208
6.

Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.

De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, Bakker WH, Smith C, Pauwels S, Krenning EP.

Semin Nucl Med. 2002 Apr;32(2):133-40. Review.

PMID:
11965608
7.

Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors.

van Essen M, Krenning EP, Kam BL, de Herder WW, Feelders RA, Kwekkeboom DJ.

J Nucl Med. 2010 Mar;51(3):383-90. doi: 10.2967/jnumed.109.068957. Epub 2010 Feb 11.

8.

Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors.

Claringbold PG, Price RA, Turner JH.

Cancer Biother Radiopharm. 2012 Nov;27(9):561-9. doi: 10.1089/cbr.2012.1276. Epub 2012 Oct 18.

PMID:
23078020
9.

Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate.

de Keizer B, van Aken MO, Feelders RA, de Herder WW, Kam BL, van Essen M, Krenning EP, Kwekkeboom DJ.

Eur J Nucl Med Mol Imaging. 2008 Apr;35(4):749-55. doi: 10.1007/s00259-007-0691-z. Epub 2008 Jan 16.

10.

[177Lu-DOTA 0-Tyr 3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney.

Swärd C, Bernhardt P, Ahlman H, Wängberg B, Forssell-Aronsson E, Larsson M, Svensson J, Rossi-Norrlund R, Kölby L.

World J Surg. 2010 Jun;34(6):1368-72. doi: 10.1007/s00268-009-0387-6.

PMID:
20066413
11.

Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate.

Khan S, Krenning EP, van Essen M, Kam BL, Teunissen JJ, Kwekkeboom DJ.

J Nucl Med. 2011 Sep;52(9):1361-8. doi: 10.2967/jnumed.111.087932. Epub 2011 Jul 27.

12.

Lutetium-labelled peptides for therapy of neuroendocrine tumours.

Kam BL, Teunissen JJ, Krenning EP, de Herder WW, Khan S, van Vliet EI, Kwekkeboom DJ.

Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1:S103-12. doi: 10.1007/s00259-011-2039-y. Review.

13.

Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate.

Sabet A, Ezziddin K, Pape UF, Ahmadzadehfar H, Mayer K, Pöppel T, Guhlke S, Biersack HJ, Ezziddin S.

J Nucl Med. 2013 Nov;54(11):1857-61. doi: 10.2967/jnumed.112.119347. Epub 2013 Sep 5.

14.

Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate.

Teunissen JJ, Kwekkeboom DJ, Krenning EP.

J Clin Oncol. 2004 Jul 1;22(13):2724-9.

PMID:
15226340
15.

Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.

Ezziddin S, Attassi M, Yong-Hing CJ, Ahmadzadehfar H, Willinek W, Grünwald F, Guhlke S, Biersack HJ, Sabet A.

J Nucl Med. 2014 Feb;55(2):183-90. doi: 10.2967/jnumed.113.125336. Epub 2014 Jan 16.

16.

Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors.

Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, Esser JP, Kam BL, Krenning EP.

J Clin Oncol. 2005 Apr 20;23(12):2754-62.

PMID:
15837990
17.

Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.

Kamp K, Gumz B, Feelders RA, Kwekkeboom DJ, Kaltsas G, Costa FP, de Herder WW.

Endocr Relat Cancer. 2013 Oct 14;20(6):825-31. doi: 10.1530/ERC-13-0254. Print 2013 Dec.

18.

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.

Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, Bartolomei M, Lombardo D, Ferrari ME, Sansovini M, Chinol M, Paganelli G.

Eur J Nucl Med Mol Imaging. 2011 Dec;38(12):2125-35. doi: 10.1007/s00259-011-1902-1. Epub 2011 Sep 3.

PMID:
21892623
19.

Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC.

Severi S, Sansovini M, Ianniello A, Bodei L, Nicolini S, Ibrahim T, Di Iorio V, D'Errico V, Caroli P, Monti M, Paganelli G.

Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):1955-63. doi: 10.1007/s00259-015-3105-7. Epub 2015 Jun 26.

PMID:
26112388
20.

A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.

Saif MW, Kaley K, Brennan M, Garcon MC, Rodriguez G, Rodriguez T.

JOP. 2013 Sep 10;14(5):498-501. doi: 10.6092/1590-8577/1589.

Supplemental Content

Support Center